| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥44.79 |
| 52 Week High | CN¥50.65 |
| 52 Week Low | CN¥31.17 |
| Beta | 0.37 |
| 11 Month Change | 10.35% |
| 3 Month Change | -4.55% |
| 1 Year Change | 23.36% |
| 33 Year Change | 109.07% |
| 5 Year Change | 94.35% |
| Change since IPO | 326.91% |
Recent News & Updates
Analysts Are Updating Their China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (SZSE:000999) Estimates After Its Second-Quarter Results
Aug 26
Does China Resources Sanjiu Medical & Pharmaceutical (SZSE:000999) Have A Healthy Balance Sheet?
Aug 09Investors Aren't Buying China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.'s (SZSE:000999) Earnings
Jul 12Recent updates
Analysts Are Updating Their China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (SZSE:000999) Estimates After Its Second-Quarter Results
Aug 26Does China Resources Sanjiu Medical & Pharmaceutical (SZSE:000999) Have A Healthy Balance Sheet?
Aug 09Investors Aren't Buying China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.'s (SZSE:000999) Earnings
Jul 12China Resources Sanjiu Medical & Pharmaceutical (SZSE:000999) Is Increasing Its Dividend To CN¥1.50
Jun 09China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Apr 23An Intrinsic Calculation For China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (SZSE:000999) Suggests It's 50% Undervalued
Apr 16Investors Aren't Buying China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.'s (SZSE:000999) Earnings
Mar 20Do China Resources Sanjiu Medical & Pharmaceutical's (SZSE:000999) Earnings Warrant Your Attention?
Feb 28Shareholder Returns
| 000999 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 5.9% | -1.8% | -2.0% |
| 1Y | 23.4% | -12.9% | -20.6% |
Return vs Industry: 000999 exceeded the CN Pharmaceuticals industry which returned -12.9% over the past year.
Return vs Market: 000999 exceeded the CN Market which returned -20.6% over the past year.
Price Volatility
| 000999 volatility | |
|---|---|
| 000999 Average Weekly Movement | 4.4% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in CN Market | 8.9% |
| 10% least volatile stocks in CN Market | 3.7% |
Stable Share Price: 000999 has not had significant price volatility in the past 3 months.
Volatility Over Time: 000999's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 20,318 | n/a | www.999.com.cn |
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in the People’s Republic of China and internationally. The company offers health consumer products (CHC), including cold, skin, gastrointestinal, cough, orthopedics, pediatrics drugs, and dietary nutritional supplements; and prescription drug products, such as anti-tumor, cardiovascular and cerebrovascular, digestive system, orthopedics, pediatrics, and other treatment areas; Chinese medicine injections; formula granules; and anti-infective drugs.
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Fundamentals Summary
| 000999 fundamental statistics | |
|---|---|
| Market cap | CN¥55.56b |
| Earnings (TTM) | CN¥3.37b |
| Revenue (TTM) | CN¥25.70b |
17.0x
P/E Ratio2.2x
P/S RatioIs 000999 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 000999 income statement (TTM) | |
|---|---|
| Revenue | CN¥25.70b |
| Cost of Revenue | CN¥11.98b |
| Gross Profit | CN¥13.72b |
| Other Expenses | CN¥10.35b |
| Earnings | CN¥3.37b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.63 |
| Gross Margin | 53.40% |
| Net Profit Margin | 13.13% |
| Debt/Equity Ratio | 11.4% |
How did 000999 perform over the long term?
See historical performance and comparison